122 related articles for article (PubMed ID: 17278224)
1. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
Witthoeft T; Fuchs M; Ludwig D
World J Gastroenterol; 2007 Jan; 13(4):579-84. PubMed ID: 17278224
[TBL] [Abstract][Full Text] [Related]
2. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
[TBL] [Abstract][Full Text] [Related]
3. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
[TBL] [Abstract][Full Text] [Related]
4. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients.
Pockros PJ; Reindollar R; McHutchinson J; Reddy R; Wright T; Boyd DG; Wilkes LB
J Viral Hepat; 2003 Jan; 10(1):55-60. PubMed ID: 12558913
[TBL] [Abstract][Full Text] [Related]
6. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
[TBL] [Abstract][Full Text] [Related]
7. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
8. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
Barbaro G; Barbarini G
Eur J Gastroenterol Hepatol; 2002 May; 14(5):477-83. PubMed ID: 11984144
[TBL] [Abstract][Full Text] [Related]
9. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
10. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
Hass HG; Kreysel C; Fischinger J; Menzel J; Kaiser S
World J Gastroenterol; 2005 Sep; 11(34):5342-6. PubMed ID: 16149143
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis.
Alavian SM; Behnava B; Tabatabaei SV
Eur J Clin Pharmacol; 2010 Nov; 66(11):1071-9. PubMed ID: 20857094
[TBL] [Abstract][Full Text] [Related]
12. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
[TBL] [Abstract][Full Text] [Related]
13. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.
Gazdik F; Gazdikova K; Laktis K; Okruhlica L; Fejdiova K; Danis D; Pijak MR; Wsolova L; Kajaba I; Kratky A
Bratisl Lek Listy; 2009; 110(2):77-84. PubMed ID: 19408838
[TBL] [Abstract][Full Text] [Related]
14. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
15. [Virological sustained response to former young intravenous drug abusers with chronic hepatitis C treated by pegylated interferon-α plus ribavirin].
Gazdíková K; Gazdík F; Kajaba I; Hučková D; Daniš D; Okruhlica L
Vnitr Lek; 2012 Feb; 58(2):104-9. PubMed ID: 22463089
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
Ray G; Pal S; Nayyar I; Dey S
Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
20. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
